VivoSim Labs, Inc. (VIVS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VivoSim Labs, Inc., a Delaware corporation, on August 17, 2026. The report addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the Company's stock price performance relative to Nasdaq listing requirements.
Material Changes and Events
- Delisting Notice: On August 17, 2026, the Company received a notice from Nasdaq stating it failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days, violating Rule 5550(a)(2).
- Compliance Period: The Company has been granted an initial 180-day period, ending February 16, 2027, to regain compliance.
- Compliance Requirement: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days within the 180-day window.
- Trading Status: The notice has no immediate effect on trading; the stock continues to trade on the Nasdaq Capital Market under the symbol "VIVS."
Outlook, Management Commentary, and Risks
Management intends to monitor the stock price and consider options to regain compliance, including a reverse stock split. A proposal for a reverse stock split with a ratio between 1-for-5 and 1-for-20 was included in the preliminary proxy statement for the 2026 Annual Meeting of Stockholders, filed on August 10, 2026, and amended on August 13, 2026.
Risks and Contingencies:
- There is no assurance that stockholders will approve the reverse stock split proposal.
- Even if approved, there is no assurance the Company will regain compliance or maintain other listing requirements.
- If the Company fails to regain compliance by February 16, 2027, it may be eligible for a second 180-day compliance period, provided it meets market value and other initial listing standards.
- Failure to cure the deficiency could result in delisting, subject to potential appeal.
Investor Verification Checklist
- Verify the outcome of the 2026 Annual Meeting of Stockholders regarding the proposed reverse stock split.
- Monitor the daily closing bid price of VIVS to track progress toward the $1.00 threshold.
- Review the Company's most recent Form 10-K and 10-Q for underlying financial health and liquidity status not detailed in this 8-K.
- Confirm whether the Company files a notice of intention to cure the bid price deficiency if the initial 180-day period expires without compliance.